## **Reyhaneh Sabourian**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3729437/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Design, Synthesis, <i>in Vitro</i> , and <i>in Silico</i> Evaluation of <i>N</i> â€Phenylacetamideâ€Oxindoleâ€Thiosemicarbazide Hybrids as New Potential Tyrosinase Inhibitors. Chemistry and Biodiversity, 2022, , .	1.0	1
2	Synthesis and molecular modeling of new 2â€benzylidenethiobarbituric acid derivatives as potent tyrosinase inhibitors agents. Journal of the Chinese Chemical Society, 2022, 69, 692-702.	0.8	6
3	<i>In vitro</i> cell-based models of drug-induced hepatotoxicity screening: progress and limitation. Drug Metabolism Reviews, 2022, 54, 161-193.	1.5	5
4	Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. International Immunopharmacology, 2021, 101, 108305.	1.7	1
5	HPLC methods for quantifying anticancer drugs in human samples: A systematic review. Analytical Biochemistry, 2020, 610, 113891.	1.1	20
6	Synthesis of Novel Tacrine Analogs as Acetylcholinesterase Inhibitors. Journal of Heterocyclic Chemistry, 2017, 54, 384-390.	1.4	19
7	Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain. Future Medicinal Chemistry, 2017, 9, 659-671.	1.1	39
8	Synthesis and biological evaluation of novel imidazopyrimidinâ€3â€amines as anticancer agents. Chemical Biology and Drug Design, 2017, 89, 797-805.	1.5	11
9	Treatment of <i>Helicobacter pylori</i> infection: Current and future insights. World Journal of Clinical Cases, 2016, 4, 5.	0.3	109
10	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery, 2016, 11, 939-956.	2.5	10
11	Novel Tacrineâ€Based Pyrano[3',4':5,6]pyrano[2,3â€ <i>b</i> ]quinolinones: Synthesis and Cholinesterase Inhibitory Activity. Archiv Der Pharmazie, 2016, 349, 915-924.	2.1	18
12	Design and synthesis of novel anti-Alzheimer's agents: Acridine-chromenone and quinoline-chromenone hybrids. Bioorganic Chemistry, 2016, 67, 84-94.	2.0	55
13	Medicinal Plants Used in Iranian Traditional Medicine (ITM) as Contraceptive Agents. Current Pharmaceutical Biotechnology, 2016, 17, 974-985.	0.9	11
14	1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study. Letters in Drug Design and Discovery, 2016, 14, 58-65.	0.4	20
15	Design, Synthesis, Biological Evaluation, and Docking Study of Acetylcholinesterase Inhibitors: New Acridoneâ€1,2,4â€oxadiazoleâ€1,2,3â€triazole Hybrids. Chemical Biology and Drug Design, 2015, 86, 1425-1432	1.5	58
16	Synthesis, antileishmanial activity and QSAR study of (1,3,4-thiadiazol-2-ylthio) acetamides derived from 5-nitrofuran. Medicinal Chemistry Research, 2015, 24, 891-900.	1.1	6
17	Synthesis and cytotoxic activity of novel poly-substituted imidazo[2,1- \$\$c\$\$ c ][1,2,4]triazin-6-amines. Molecular Diversity, 2015, 19, 273-281.	2.1	20
18	Potent acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, and docking study of acridone linked to 1,2,3-triazole derivatives. European Journal of Medicinal Chemistry, 2015, 92, 799-806.	2.6	91

**Reyhaneh Sabourian** 

#	Article	IF	CITATIONS
19	Design, synthesis, in vitro cytotoxic activity evaluation, and apoptosis-induction study of new 9(10H)-acridinone-1,2,3-triazoles. Molecular Diversity, 2015, 19, 787-795.	2.1	41
20	Synthesis of Novel 1,2,3-Triazole-dihydro[3,2- <i>c</i> ]chromenones as Acetylcholinesterase Inhibitors. Synthetic Communications, 2015, 45, 2311-2318.	1.1	29
21	Synthesis and evaluation of novel oxoisoindoline derivatives as acetylcholinesterase inhibitors. Monatshefte Für Chemie, 2015, 146, 637-643.	0.9	20